Androgen Therapy Increases Responses to Sildenafil in Hypogonadal Patients

Ti-S Hwang1,2,3, H-E Chen1, T-F Tsai1 and Y C Lin1

  1. 1Division of Urology, Department of Surgery, Shin Kong WHS Memorial Hospital, Taipei, Taiwan
  2. 2Department of Urology, Taipei Medical University, Taipei, Taiwan
  3. 3Department of Urology, College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan

Correspondence: Dr TI-S Hwang, Division of Urology, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, No. 95 Wen Chang Road, Taipei, Taiwan 111, ROC.

Received 21 September 2005; Revised 2 December 2005; Accepted 5 December 2005; Published online 5 January 2006.


To investigate the therapeutic effect of androgen on hypogonadal patients unresponsive to sildenafil alone. In total, 32 hypogonadal patients with erectile dysfunction (ED), initially had an inadequate response to sildenafil (100 mg). Oral testosterone undecanoate (Restandol®, 80 mg, bid or tid) alone was supplied for 2 months, and if patients could not achieve a satisfactory erection, combined use of testosterone and sildenafil was continued thereafter. Total testosterone (TT), free testosterone (FT), and the parameters of the International Index of Erectile Function (IIEF), International Prostate Symptom Score (IPSS), and uroflow rate (UFR) were assessed. Eleven patients (34.3%) achieved satisfactory erectile function after testosterone replacement only. Another 12 (37.5%) patients experienced satisfactory intercourse after combined therapy. Serum TT and FT levels significantly increased after the use of testosterone alone (415plusminus163 vs 220plusminus101 ng/dl, P<0.01; 10.4plusminus4.6 vs 5.1plusminus1.9 ng/dl; P<0.01, respectively) and the combined use of testosterone and sildenafil (498plusminus178 vs 220plusminus101 ng/dl, P<0.01; 11.7plusminus4.6 vs 5.1plusminus1.9 ng/dl, P<0.001, respectively); as did the IIEF score (14.8plusminus6.8 vs 12.6plusminus7.5, P<0.01, 17.5plusminus5.2 vs 12.6plusminus7.5, P<0.001, respectively). However, no statistical differences were demonstrated for IPSS or UFR. In conclusions, one-third of hypogonadal patients with ED who failed to respond to sildenafil, responded to testosterone alone, another third responded to sildenafil again after normalization of testosterone. So, in hypogonadal patients with ED, androgen supplementation is first-line therapy. If patients are unresponsive to androgen alone or sildenafil alone, combined use may improve erectile function and enhance the therapeutic effect of PDE-5 inhibitors.

This is just an abstract, for full article you may want to visit link below

About yuan ade sukma, MD

I'm an Indonesian doctor. I Believe that science and knowledge do not belong to anyone in the world. Science and knowledge is meant to be shared to make the world a better place to live. But if you find any material posted here is violating any copyrights, feel free to contact me and I will delete that. I believe that someday my blog can change the world. I BELIEVE in the POWER of WORDS! Do you..?
Gallery | This entry was posted in Andrology Latest Update and tagged , , , , , . Bookmark the permalink.

2 Responses to Androgen Therapy Increases Responses to Sildenafil in Hypogonadal Patients

  1. Edward says:

    Nice article thanks for sharing ..

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s